trending Market Intelligence /marketintelligence/en/news-insights/trending/pa-Hshv0LZE4nIqEVZM5zA2 content esgSubNav
In This List

Glenmark secures US FDA approval for another generic hypertension drug

Podcast

Private Markets 360° | Episode 8: Powering the Global Private Markets (with Adam Kansler of S&P Global Market Intelligence)

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Glenmark secures US FDA approval for another generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured U.S. Food and Drug Administration approval to market a generic version of Allergan PLC's hypertension drug Bystolic.

Glenmark will launch its Nebivolol tablets three months before Bystolic's patent expires as part of a settlement agreement with Allergan.

Bystolic generated annual sales of $1 billion in the 12-month period ending March 2017, according to IMS Health Holdings Inc. data.

Glenmark Pharmaceuticals also recently secured U.S. FDA approval to market a generic version of Benicar, Daiichi Sankyo Co. Ltd.'s hypertension drug.